Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion

Open access
Tien, Jerry F., Mazloomian, Alborz, Cheng, S.-W. Grace, Hughes, Christopher S., Chow, Christalle C.T., Canapi, Leanna T., Oloumi, Arusha, Trigo-Gonzalez, Genny, Bashashati, Ali, Xu, James, Chang, Vicky C.-D., Shah, Sohrab P., Aparicio, Samuel, Morin, Gregg B. · 2017 · Nucleic Acids Research

Abstract

CDK12 (cyclin-dependent kinase 12) is a regulatory kinase with evolutionarily conserved roles in modulating transcription elongation. Recent tumor genome studies of breast and ovarian cancers highlighted recurrent CDK12 mutations, which have been shown to disrupt DNA repair in cell-based assays. In breast cancers, CDK12 is also frequently co-amplified with the HER2 (ERBB2) oncogene. The mechanisms underlying functions of CDK12 in general and in cancer remain poorly defined. Based on global analysis of mRNA transcripts in normal and breast cancer cell lines with and without CDK12 amplification, we demonstrate that CDK12 primarily regulates alternative last exon (ALE) splicing, a specialized subtype of alternative mRNA splicing, that is both gene- and cell type-specific. These are unusual properties for spliceosome regulatory factors, which typically regulate multiple forms of alternative splicing in a global manner. In breast cancer cells, regulation by CDK12 modulates ALE splicing of the DNA damage response activator ATM and a DNAJB6 isoform that influences cell invasion and tumorigenesis in xenografts. We found that there is a direct correlation between CDK12 levels, DNAJB6 isoform levels and the migration capacity and invasiveness of breast tumor cells. This suggests that CDK12 gene amplification can contribute to the pathogenesis of the cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/nar/gkx187

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 163

Metadata

Authors
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., Chang, V. C.-D., Shah, S. P., Aparicio, S., & Morin, G. B.
Venue
Nucleic Acids Research
Published
2017-03-17
Volume
45
Issue
11
Pages
6698-6716
ISSN
  • 0305-1048 (ISSN-L)
  • 1362-4962
OpenAlex
W2596759372
Cited by
163
References
19
FWCI
6.21
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. https://app.cochat.ai/papers/10.1093/nar/gkx187
The paper
Tien, J. F., Mazloomian, A., Cheng, S.-W. G., Hughes, C. S., Chow, C. C. T., Canapi, L. T., Oloumi, A., Trigo-Gonzalez, G., Bashashati, A., Xu, J., Chang, V. C.-D., Shah, S. P., Aparicio, S., & Morin, G. B. (2017). CDK12 regulates alternative last exon mRNA splicing and promotes breast cancer cell invasion. Nucleic Acids Research. https://doi.org/10.1093/nar/gkx187

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.